Gemini Therapeutics (GMTX) News Today → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free GMTX Stock Alerts $30.36 -0.41 (-1.33%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineGoogle's public release of Gemini 1.5 should build trust, Deutsche Bank saysseekingalpha.com - April 17 at 8:53 AMGemini Therapeutics (NASDAQ:GMTX) Hits New 1-Year High at $32.55marketbeat.com - April 15 at 8:20 PMGemini Therapeutics (NASDAQ:GMTX) Sets New 1-Year High at $31.92marketbeat.com - April 8 at 9:21 PMGemini Therapeutics (NASDAQ:GMTX) Reaches New 1-Year High at $35.40marketbeat.com - April 1 at 7:33 PMGemini Therapeutics (NASDAQ:GMTX) Sets New 1-Year High at $60.96marketbeat.com - March 25 at 7:46 PMGemini Therapeutics (NASDAQ:GMTX) Hits New 12-Month High at $67.76marketbeat.com - March 19 at 8:39 PMGemini Therapeutics (NASDAQ:GMTX) Hits New 52-Week High at $66.32marketbeat.com - March 13 at 7:27 PMGoogle takes down Gemini AI image generator. Here’s what you need to know.washingtonpost.com - February 26 at 7:46 AM‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiasconypost.com - February 26 at 7:46 AM(SPAC) Special Purpose Acquisition Investigation: PRDS, GMTX, SNTI, TNGX - Contact Shareholder Rights Law Firm Johnson Fistelbenzinga.com - June 24 at 2:58 PMBronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigationbarrons.com - June 1 at 10:41 PMGemini Therapeutics, Inc. (NASDAQ:GMTX) Shares Sold by Ergoteles LLCmarketbeat.com - March 8 at 4:50 AMAssenagon Asset Management S.A. Acquires 66,467 Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX)marketbeat.com - January 19 at 4:42 AMThe Winklevoss' Gemini terminates its yield product as dispute between the crypto exchange and DCG escalatesmarkets.businessinsider.com - January 13 at 1:47 PMGemini Horoscopeusatoday.com - January 1 at 7:28 AMDisc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyriafinance.yahoo.com - December 27 at 10:14 AMDisc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)finance.yahoo.com - October 31 at 10:03 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBTX, PBFX, EVOP, GMTXbenzinga.com - September 27 at 1:31 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFYbenzinga.com - September 26 at 1:24 AMSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates GMTX, RMED, LOTZmarkets.businessinsider.com - September 16 at 9:31 AMSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BHVN, DRE, PLD, GMTX, SAFEmarkets.businessinsider.com - September 6 at 10:12 AMThe M&A Class Action Firm Announces the Investigation of Gemini Therapeutics, Inc. – GMTXapnews.com - August 25 at 12:31 AMSHAREHOLDER ALERT: Weiss Law Reminds, LOTZ, GMTX, AAWW, and CCXI Shareholders About Its Ongoing Investigationsbenzinga.com - August 24 at 7:30 PMGEMINI THERAPEUTICS, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of GMTX and Encourages Investors to Contact the Firmapnews.com - August 12 at 9:57 PMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Gemini Therapeutics, Inc. Mergermarketwatch.com - August 12 at 6:55 AMSHAREHOLDER ALERT: Weiss Law Investigates Gemini Therapeutics, Inc.benzinga.com - August 11 at 3:51 PMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZapnews.com - August 11 at 6:58 AMGMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to Shareholdersapnews.com - August 11 at 1:57 AMSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Gemini Therapeutics, Inc. (Nasdaq – GMTX)apnews.com - August 10 at 3:53 PMBlood disorder startup goes public by merging with embattled biotechfinance.yahoo.com - August 10 at 3:53 PMGemini stock soars 35% on merger with Disc Medicine in all-stock dealseekingalpha.com - August 10 at 10:53 AMGemini Therapeutics, Disc Medicine Announce All-stock Mergernasdaq.com - August 10 at 10:53 AMGemini Therapeutics and Disc Medicine Announce Merger Agreementfinance.yahoo.com - August 10 at 10:53 AMmarketbeat.com - August 10 at 7:34 AMInsider Buying: Braden Leonard Just Spent US$75k On Gemini Therapeutics, Inc. (NASDAQ:GMTX) Sharesfinance.yahoo.com - April 15 at 9:32 AMGemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?finance.yahoo.com - April 12 at 2:18 PMHC Wainwright Lowers Gemini Therapeutics (NASDAQ:GMTX) to Neutralmarketbeat.com - March 11 at 7:35 AMGemini Therapeutics GAAP EPS of -$1.78 beats by $0.17seekingalpha.com - March 10 at 9:25 AMGemini Therapeutics Reports 2021 Financial Resultsfinance.yahoo.com - March 10 at 9:25 AMGemini Therapeutics (NASDAQ:GMTX) Upgraded to "Buy" by Zacks Investment Researchmarketbeat.com - March 7 at 11:54 PMWhat 5 Analyst Ratings Have To Say About Gemini Therapeuticsbenzinga.com - March 3 at 7:37 PMTwo more Cambridge biotechs cutting staffbizjournals.com - March 2 at 4:51 PMAPi Group Shares Slide After Q4 Results, Clocks 27% Revenue Growthuk.investing.com - March 1 at 3:35 PMJefferies Downgrades Gemini Therapeutics to Hold, Lowers Price Target to $1.5benzinga.com - March 1 at 3:35 PMGemini extends losses as strategic review prompts Jefferies downgradeseekingalpha.com - March 1 at 3:35 PMGemini Therapeutics names interim CEO, announces job cutsseekingalpha.com - February 28 at 10:41 AMGemini Therapeutics Provides Corporate Updatefinance.yahoo.com - February 28 at 10:41 AMSVB Leerink Maintains Outperform on Gemini Therapeutics, Lowers Price Target to $10benzinga.com - January 25 at 4:51 AMGemini Therapeutics (NASDAQ:GMTX) Price Target Lowered to $10.00 at SVB Leerinkmarketbeat.com - January 24 at 8:26 AMGemini Therapeutics, Inc. Common Stock (GMTX)nasdaq.com - January 11 at 9:16 PM Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market. Click here to get instant access to the guide GMTX Media Mentions By Week GMTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMTX News Sentiment▼0.000.58▲Average Medical News Sentiment GMTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMTX Articles This Week▼00▲GMTX Articles Average Week Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Ligand Pharmaceuticals News Ironwood Pharmaceuticals News Gyre Therapeutics News Prothena News Belite Bio News Spyre Therapeutics News Pacira BioSciences News Mirum Pharmaceuticals News Collegium Pharmaceutical News MannKind News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMTX) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICElon to Transform U.S. Economy? Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
